| | TOP STORY | Combination Overcomes Breast Cancer Resistance to Herceptin
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor’s vulnerability to treatment, scientists report. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Nature Medicine]  |
| | SCIENCE NEWS | Whitehead Scientist Helps Revisit “Hallmarks of Cancer”
Renowned cancer researchers Robert Weinberg and Douglas Hanahan have updated their seminal review, “Hallmarks of Cancer,” which has influenced the study of cancer and the development of therapeutics for more than a decade. [Press release from the Whitehead Institute for Biomedical Research discussing online prepublication in Cell] Tiny Gems Take Big Step in Battling Cancer
In studies of liver and breast cancer models in vivo, a multidisciplinary team found that a normally lethal amount of a chemotherapy drug when bound to nanodiamonds significantly reduced the size of tumors in mice. [Press release from Northwestern University discussing online prepublication in Science Translational Medicine] Breast Cancer May Not Change Lifespan for Older Women
Older women who are diagnosed with early-stage breast cancer can expect to live just as long as peers without breast cancer, according to a new study. [Press release from Reuters Health discussing online prepublication in the Journal of Clinical Oncology] Combination Treatment for DCIS Breast Cancer Improves Survival Rates, Scientist Reports
Women with a localized type of breast cancer called ductal carcinoma in situ (DCIS) who are treated by breast-conserving or lumpectomy surgery with radiation therapy and tamoxifen fare better in the subsequent decades than those who undergo lumpectomy alone. [Press release from the Stanford University School of Medicine discussing online prepublication in the Journal of the National Cancer Institute] Taking Tamoxifen to Prevent Breast Cancer Can Save Lives and Money
Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs. [Press release from Wiley Online Library discussing online prepublication in Cancer]
New Radiotherapy Technique May Save More Healthy Breast Tissue
A new study will confirm whether an advanced radiotherapy technique that uses imaging of titanium clips implanted during surgery can reduce side-effects from breast cancer treatment. [The Institute of Cancer Research Press Release]  |
| | CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) | LABORATORY RESEARCH Hallmarks of Cancer: The Next Generation
The hallmarks of cancer constitute an organizing principle for rationalizing the complexities of neoplastic disease. Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list – reprogramming of energy metabolism and evading immune destruction. [Cell]
Combating Trastuzumab Resistance by Targeting SRC, a Common Node Downstream of Multiple Resistance Pathways
Scientists show that the nonreceptor tyrosine kinase c-SRC (SRC) is a key modulator of trastuzumab response and a common node downstream of multiple trastuzumab resistance pathways. [Nat Med]
SIRT3 Opposes Reprogramming of Cancer Cell Metabolism through Hypoxia-Inducible Factor-1α Destabilization
Here, researchers show that the mitochondrial NAD-dependent deacetylase SIRT3 is a crucial regulator of the Warburg effect. [Cancer Cell]
High Levels of the Mps1 Checkpoint Protein Are Protective of Aneuploidy in Breast Cancer Cells
Noting that aneuploidy in human breast cancer correlates with increased expression levels of the Mps1 checkpoint gene, scientists investigated whether these high levels of Mps1 contribute to the ability of breast cancer cells to tolerate this aneuploidy. [Proc Natl Acad Sci U S A] Transcriptional and Posttranslational Up-Regulation of HER3 (ErbB3) Compensates for Inhibition of the HER2 Tyrosine Kinase
Investigators show that, after inhibition of the HER2 tyrosine kinase with lapatinib, there is PI3K/Akt and FoxO3a-dependent up-regulation of HER3 mRNA and protein. [Proc Natl Acad Sci U S A]
The ΔNp63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer
Here researchers report that ΔNp63 isoforms of p63 are transcriptional targets for positive regulation by BRCA1. [Cancer Res]
Loss of BRCA1 Leads to an Increase in Epidermal Growth Factor Receptor Expression in Mammary Epithelial Cells, and Epidermal Growth Factor Receptor-Inhibition Prevents Estrogen Receptor-Negative Cancers in BRCA1-Mutant Mice
Here investigators examine the role of epidermal growth factor receptor in mammary epithelial cells in the emergence of BRCA1-related tumors and as a potential target for the prevention of “triple-negative” breast cancers. [Breast Cancer Res]
Bioengineering Embryonic Stem Cell Microenvironments for Exploring Inhibitory Effects on Metastatic Breast Cancer Cells
In this study, scientists explore the feasibility of reconstructing embryonic microenvironments using mouse embryonic stem cells cultured in alginate hydrogel and investigated the interactions of embryonic stem cells and highly invasive breast cancer cells in 2D, 2&1/2D, and 3D cultures. [Biomaterials]
Mutation of Thyroid Hormone Receptor-β in Mice Predisposes to the Development of Mammary Tumors
To explore the role of thyroid hormone receptor-β (TRβ) mutants in vivo in breast tumor development and progression, researchers took advantage of a knock-in mouse model harboring a mutation in the Thrb gene encoding TRβ (ThrbPV mouse). [Oncogene]
Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
Here, investigators examine the efficacy of a nanodiamond-conjugated chemotherapeutic in mouse models of liver and mammary cancer. [Sci Transl Med]
CLINICAL RESEARCH Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
Scientists evaluated invasive ipsilateral breast tumor recurrence and its influence on survival among participants in two National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized trials for ductal carcinoma in situ (DCIS). [J Natl Cancer Inst]
Declining Incidence of Contralateral Breast Cancer in the United States From 1975 to 2006
Results show a favorable decrease of 3% per year for contralateral breast cancer incidence in the United States since 1985. [J Clin Oncol]
Causes of Death and Relative Survival of Older Women After a Breast Cancer Diagnosis
To understand the impact of breast cancer on older women’s survival, investigators compared survival of older women diagnosed with breast cancer with matched controls. [J Clin Oncol]
Cost-Effectiveness of Chemoprevention of Breast Cancer Using Tamoxifen in a Postmenopausal U.S. Population
A detailed, continuous time, mathematical model of breast cancer and healthcare processes was used to simulate a postmenopausal population aged less than 55 years in a virtual trial comparing tamoxifen treatment with no treatment for lifetime follow-up. [Cancer]
Randomized Phase II Trial of Gemcitabine Plus Vinorelbine vs Gemcitabine Plus Cisplatin vs Gemcitabine Plus Capecitabine in Patients with Pretreated Metastatic Breast Cancer
This randomized Phase II trial has revealed comparable results for three gemcitabine-based regimens regarding treatment efficacy and toxicity. [Br J Cancer] |
| | INDUSTRY NEWS | MD Anderson and the National Cancer Institute of Peru Sign Sister Institution Agreement in Cancer Treatment and Research
The University of Texas MD Anderson Cancer Center signed a sister institution agreement with the National Cancer Institute of Peru. The agreement formalizes plans to collaborate on groundbreaking achievements in cancer research and care that will benefit patients in the United States, Latin America and around the world. [The University of Texas MD Anderson Cancer Center Press Release] OncoVista Innovative Therapies Outlines Business Strategy; “Company Is Moving Full-Speed Ahead,” Says CEO
OncoVista Innovative Therapies, Inc., reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity. [OncoVista Innovative Therapies, Inc. Press Release]
Steven C. Quay, M.D., Ph.D., of Atossa Genetics Elected as a Fellow of the College of American Pathologists
Atossa Genetics, Inc. announced that Steven C. Quay, M.D., Ph.D., Chairman, President and CEO, has been elected as a Fellow of the College of American Pathologists (FCAP). [Atossa Genetics, Inc. Press Release]
3D Mammography Now Available at the Breast Health and Research Center
Valley women will have access by early April to the nation’s first lifesaving three-dimensional mammography at John C. Lincoln’s Breast Health and Research Center, director Sherry Gage, RTRM, announced. [John C. Lincoln Health Network Press Release] |
| | EVENTS | NEW BIT’s 4th Annual World Cancer Congress 2011
May 22-26, 2011
Dalian, China NEW World Conference on Breast Cancer Foundation
June 7-11, 2011
Hamilton, Canada NEW Molecular Diagnostics for Cancer Drug Development
June 28-30, 2011
Boston, United States NEW 2nd International Symposium on Breast Cancer Prevention: Epigenome, Nutrition, and Public Policy
October 9-11, 2011
Rennes, France Visit our events page to see a complete list of events in the mammary cell community. |
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
